- Home
- GLTO vs TOVX Comparison
GLTO vs TOVX Comparison
Compare GLTO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- TOVX
- Stock Information
- Founded
- GLTO 2011
- TOVX 2001
- Country
- GLTO Denmark
- TOVX United States
- Employees
- GLTO N/A
- TOVX N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- TOVX Health Care
- Exchange
- GLTO Nasdaq
- TOVX Nasdaq
- Market Cap
- GLTO 4.5M
- TOVX 3.8M
- IPO Year
- GLTO 2020
- TOVX 2006
- Fundamental
- Price
- GLTO $3.54
- TOVX $0.50
- Analyst Decision
- GLTO Buy
- TOVX Hold
- Analyst Count
- GLTO 1
- TOVX 1
- Target Price
- GLTO $10.00
- TOVX N/A
- AVG Volume (30 Days)
- GLTO 13.7K
- TOVX 170.1K
- Earning Date
- GLTO 08-11-2025
- TOVX 08-12-2025
- Dividend Yield
- GLTO N/A
- TOVX N/A
- EPS Growth
- GLTO N/A
- TOVX N/A
- EPS
- GLTO N/A
- TOVX N/A
- Revenue
- GLTO N/A
- TOVX N/A
- Revenue This Year
- GLTO N/A
- TOVX N/A
- Revenue Next Year
- GLTO N/A
- TOVX N/A
- P/E Ratio
- GLTO N/A
- TOVX N/A
- Revenue Growth
- GLTO N/A
- TOVX N/A
- 52 Week Low
- GLTO $2.01
- TOVX $0.40
- 52 Week High
- GLTO $16.07
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- GLTO 59.96
- TOVX 45.57
- Support Level
- GLTO $3.24
- TOVX $0.42
- Resistance Level
- GLTO $3.60
- TOVX $0.48
- Average True Range (ATR)
- GLTO 0.26
- TOVX 0.03
- MACD
- GLTO -0.01
- TOVX 0.02
- Stochastic Oscillator
- GLTO 60.98
- TOVX 88.67
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.